SeaStar Medical reported a net loss of $11.8 million for the nine months ended September 30, 2026, compared to $9.2 million in the prior year period, driven by increased research and development expenses. Total revenue grew to $1.7 million from $0.8 million year-over-year, while cash reserves decreased significantly to $4.0 million from $12.0 million at the start of the year.
SeaStar Medical reported Q3 2026 financial results, highlighted by a 247% increase in net revenue to $635,000 driven by adoption of its QUELIMMUNE therapy. The company also announced that its NEUTRALIZE-AKI pivotal clinical trial for adult patients is nearly 75% enrolled and it has submitted the first module of its PMA application to the FDA.
Term
Q3 2026
“The strength of the QUELIMMUNE therapy adoption in this ultra-rare pediatric AKI market provides great promise for our pipeline indications. And we continue to build momentum in educating the critical care pediatric health care community.”
Eric Schlorff, CEO of SeaStar Medical
“The NEUTRALIZE-AKI pivotal clinical trial has enrolled nearly 75% of its intended 339 patients, and we have already submitted the first module of the premarket approval application to the FDA in hopes that our modular submission will speed this potential approval.”
SeaStar Medical announced that the FDA's Center for Biologics Evaluation and Research (CBER) determined the QUELIMMUNE Pediatric SAVE Surveillance Registry has fulfilled its post-approval study requirements. This decision allows hospitals to use the QUELIMMUNE therapy for pediatric sepsis-associated acute kidney injury without the research infrastructure previously required by the registry, significantly expanding patient access.